|BioClinica CEO John Hubbard|
BioClinica has inked a deal with consulting firm Kinapse to help spread the adoption of its risk-based monitoring service, a targeted approach to keeping tabs on trials.
Under the partnership, Kinapse is on board to offer its services in easing the transition to risk-based monitoring, or RBM, for study sponsors. Compass, BioClinica's RBM platform, is designed to focus study resources on the sites most likely to pose risks to its overall success, managing time and effort in the monitoring process.
"Implementing a comprehensive RBM solution can make a real difference in clinical research," BioClinica CEO John Hubbard said in a statement. "We're excited about this collaboration as it helps move the industry forward with intelligent monitoring by bringing together our technology and subject matter expertise with Kinapse's broad implementation experience."
BioClinica got its hands on Compass in last year's acquisition of Blueprint Clinical. That agreement came on the heels of a 2014 buyout of CCBR-Synarc that stretched BioClinica's focus to include medical imaging and specialty services for clinical trials.
The acquisitive BioClinica has spent the last few years buying up new technologies, including offerings in electronic data collection, patient randomization and supply management.
Private equity firm JLL Partners bought BioClinica for $123 million in 2013 and subsequently merged the company with CoreLab, owned by Ampersand Capital Partners, which kept its stake in the combined outfit.
BioClinica said its eClinical sales jumped 51% last year, reflecting a spike in Big Pharma's adoption of new trial technologies. The company reported 25 new partnerships last year and now boasts a client roster of more than 150, and its string of buyouts have grown its payroll to more than 1,300 people around the world.
- read the statement